For many heart failure patients, diuretics are self-defeating; they activate a fluid-conservation mechanism that both limits drugs' effectiveness and damages kidneys. So great is the need for kidney-preserving diuretics that when a partner at Domain Associates learned of a promising drug candidate, he founded NovaCardia to develop it.
12651 High Bluff Drive
Suite 200
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.
In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.
One Phase III trial hits but a second study misses by a mile.
